Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 4/20 | 0.50 |
| ▸ | EGFR known ✓ | P00533 | 2/20 | 0.50 |
| ▸ | MMP8 known ✓ | P22894 | 1/20 | 0.50 |
| ▸ | PIK3CA known ✓ | P42336 | 1/20 | 0.47 |
| ▸ | G6PD | P11413 | 1/20 | 0.54 |
| ▸ | CASP7 | P55210 | 1/20 | 0.54 |
| ▸ | CASP6 | P55212 | 1/20 | 0.54 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | HPGD | P15428 | 3/20 | 0.50 |
| ▸ | RECQL | P46063 | 3/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.50 |
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | CA1 | P00915 | 3/20 | 0.50 |
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | FYN | P06241 | 2/20 | 0.50 |
| ▸ | MMP9 | P14780 | 2/20 | 0.50 |
| ▸ | ADAMTS4 | O75173 | 1/20 | 0.50 |
| ▸ | MMP2 | P08253 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL69654 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL27614139 | 0.87 | TRPA1 (0.54) | G6PDCASP7CASP6TDP1ALOX15 | |
| Hydrochloric Acid SCHEMBL30811553 | 0.87 | TRPA1 (0.54) | G6PDCASP7CASP6TDP1ALOX15 | |
| Hydrochloric Acid SCHEMBL7691097 | 0.85 | ALOX15 (0.57) | G6PDCASP7CASP6TDP1ALOX15 | |
| Hydrochloric Acid SCHEMBL3000038 | 0.85 | ALOX15 (0.57) | G6PDCASP7CASP6TDP1ALOX15 | |
| SCHEMBL29486565 | 0.83 | — | — | |
| SCHEMBL103071 | 0.83 | — | — | |
| SCHEMBL190980 | 0.81 | — | — | |
| SCHEMBL564030 | 0.81 | CASP7 (0.50) | G6PDCASP7CASP6TDP1ALOX15 | |
| SCHEMBL29623283 | 0.81 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 103 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200205541-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | L'OREAL (FR) | 2020-07-02 | — | — | US | claimed |
| US-20130298933-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | L'OREAL (FR) | 2013-11-14 | — | — | US | claimed |
| US-20100300472-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | L'OREAL S.A. (FR) | 2010-12-02 | — | — | US | claimed |
| CN-101397279-A | Method for preparing acanthus alkaloid A with anti inflammatory and analgesic activities and derivatives thereof | UNIV GUANGXI MEDICAL (CN) | 2009-04-01 | — | — | CN | claimed |
| EP-4554549-A1 | COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT OR CELLULOSE COMPOUND | L'OREAL (FR) | 2025-05-21 | — | — | EP | disclosed |
| CN-119677492-A | Composition comprising a skin care active or a cellulose compound | 莱雅公司 | 2025-03-21 | — | — | CN | disclosed |
| US-20250064703-A1 | COMPOSITION COMPRISING SOLUBILIZED POLYPHENOL | OREAL (FR) | 2025-02-27 | — | — | US | disclosed |
| EP-4452205-A1 | COMPOSITION COMPRISING SOLUBILIZED POLYPHENOL | L'OREAL (FR) | 2024-10-30 | — | — | EP | disclosed |
| CN-118542820-A | Topical delivery system for active ingredients | 莱雅公司 | 2024-08-27 | — | — | CN | disclosed |
| CN-118414140-A | Compositions comprising dissolved polyphenols | 莱雅公司 | 2024-07-30 | — | — | CN | disclosed |
| EP-4337159-A1 | COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT AND TWO POLYGLYCERYL FATTY ACID ESTERS | L'OREAL (FR) | 2024-03-20 | — | — | EP | disclosed |
| WO-2024014310-A1 | COMPOSITION COMPRISING SKIN CARE ACTIVE INGREDIENT OR CELLULOSE COMPOUND | L'OREAL (FR) | 2024-01-18 | — | — | WO | disclosed |
| EP-0681216-A1 | Photographic colour developing process | Agfa-Gevaert AG (DE) | 1995-11-08 | — | — | EP | disclosed |
| CN-1023320-C | Process for preparing a benzoxazinnorifamycim derivative | KANEGAFUCHI CHEMICAL IND (JP) | 1993-12-29 | — | — | CN | disclosed |
| CN-1059145-A | 3 '-alkyl or aryl siloxy-benzoxazine and Ryfamycin derivative | KANEGAFUCHI CHEMICAL IND (JP) | 1992-03-04 | — | — | CN | disclosed |
| EP-0190709-B1 | BENZOXAZINORIFAMYCIN DERIVATIVE, PROCESS FOR PREPARING THE SAME AND ANTI-BACTERIAL AGENT CONTAINING THE SAME | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1989-12-06 | — | — | EP | disclosed |
| US-4690919-A | Benzoxazinorifamycin derivative, process for preparing the same and antibacterial agent containing the same | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1987-09-01 | — | — | US | disclosed |
| CN-86103776-A | Process for preparing benzoxazinorifamycin derivatives | — | 1987-08-05 | — | — | CN | disclosed |
| EP-0190709-A1 | Benzoxazinorifamycin derivative, process for preparing the same and anti-bacterial agent containing the same | KANEGAFUCHI KAGAKU KOGYO KABUSHIKI KAISHA (JP) | 1986-08-13 | — | — | EP | disclosed |
| US-4126461-A | NONDIFFUSIBLE RESORCINOL COUPLER | EASTMAN KODAK COMPANY (US) | 1978-11-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200205541-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | KRT18, TUBB4A, TUBB4B | CA2 2393/4885EGFR 751/4885MMP8 1853/4885 |
| US-20250064703-A1 | COMPOSITION COMPRISING SOLUBILIZED POLYPHENOL | PROC, GANC, LGALS1 | CA2 754/4885EGFR 4672/4885MMP8 2228/4885 |
| US-20100300472-A1 | METHOD FOR STRAIGHTENING KERATINOUS FIBERS USING HEATING MEANS AND AN AROMATIC COMPOUND | KRT18, TUBB4A, TUBB4B | CA2 2393/4885EGFR 751/4885MMP8 1853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.